Stocks · News reference
HealthEquity shares are trading lower after the company issued Q2 financial results. The company affirmed its FY27 adjusted EPS guidance with its midpoint below estimates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why HealthEquity Stock Sank This Week
HealthEquity stock fell 8.6% this week despite delivering sales and earnings beats in its fiscal Q2 report. The company posted adjusted EPS of $1.24 on revenue of $350.7 million, both exceeding analyst expectations. However, management's marginal increase to full-year revenue guidance and unchanged adjusted EPS guidance disappointed investors who were expecting stronger forward guidance.
BTIG Reiterates Buy on HealthEquity, Maintains $115 Price Target
BTIG analyst David Larsen reiterates HealthEquity (NASDAQ:HQY) with a Buy and maintains $115 price target.
Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings
U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings. European and Asian markets closed mostly lower.